Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1
Autor(a) principal: | |
---|---|
Data de Publicação: | 2013 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Vigilância Sanitária em Debate |
Texto Completo: | https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89 |
Resumo: | In this study we compared the outcomes of epoetin alpha (rhEPO) potency assays performed with Swiss Webster, NIH, C57BL/6 and BALB/c mice with those of the assay conducted with the B6D2F1 hybrid, the only mice recommended by the European Pharmacopoeia (EP). Female mice from different breeding stocks and strains, weighing 16-18 g, received a single subcutaneous injection of (30, 90 or 270 IU per mouse, 0.2 mL per mouse) of rhEPO. Biological potencies of 4000 IU/mL rhEPO pharmaceutical forms from different batches were determined using a biological reference preparation (3773 IU/mL) previously tested against the international reference standard BRP (European Pharmacopoeia Biological Reference Preparation). Results showed that assays with mice from all tested breeding stocks and strains met EP statistical criteria for a valid erythropoietin potency assay and thus they are potential alternatives to the use of B6D2F1 hybrids. The assays with BALB/c mice, however, were those the results of which were most similar to those obtained with the hybrid regarding average reticulocyte counts in response to 30, 90 and 270 IU/mouse, angular (slope) and linear (intersection) coefficients of the linear dose-response curve (parallel and almost complete overlapping dose-response curves). |
id |
FIOCRUZ-9_9ea7fd1f5388f8747b0fc6a2771cb4b1 |
---|---|
oai_identifier_str |
oai:ojs.visaemdebate.incqs.fiocruz.br:article/89 |
network_acronym_str |
FIOCRUZ-9 |
network_name_str |
Vigilância Sanitária em Debate |
repository_id_str |
|
spelling |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1Ensaio de potência da alfaepoetina: Comparação de camundongos Swiss Webster, NIH, C57BL6, BALB/c com o híbrido B6D2F1epoetin alphaPotency assaybioassaymouse strainshuman erythropoietin recombinant (rhEPO)Alfaepoetinaensaio de potênciabioensaiolinhagens de camundongoseritropoietina recombiante humana (EPOhr)In this study we compared the outcomes of epoetin alpha (rhEPO) potency assays performed with Swiss Webster, NIH, C57BL/6 and BALB/c mice with those of the assay conducted with the B6D2F1 hybrid, the only mice recommended by the European Pharmacopoeia (EP). Female mice from different breeding stocks and strains, weighing 16-18 g, received a single subcutaneous injection of (30, 90 or 270 IU per mouse, 0.2 mL per mouse) of rhEPO. Biological potencies of 4000 IU/mL rhEPO pharmaceutical forms from different batches were determined using a biological reference preparation (3773 IU/mL) previously tested against the international reference standard BRP (European Pharmacopoeia Biological Reference Preparation). Results showed that assays with mice from all tested breeding stocks and strains met EP statistical criteria for a valid erythropoietin potency assay and thus they are potential alternatives to the use of B6D2F1 hybrids. The assays with BALB/c mice, however, were those the results of which were most similar to those obtained with the hybrid regarding average reticulocyte counts in response to 30, 90 and 270 IU/mouse, angular (slope) and linear (intersection) coefficients of the linear dose-response curve (parallel and almost complete overlapping dose-response curves).Neste estudo comparamos ensaios de potência da alfaepoetina realizados com camundongos de diferentes colônias e linhagens (Swiss Webster, NIH, C57BL6, BALB/c e híbrido B6D2F1). Os testes foram efetuados com fêmeas pesando 16-18 gramas, tratadas com dose única de alfaepoetina por via subcutânea (30, 90 e 270 UI/ animal). O sangue foi coletado 96 horas após a injeção (72 horas no caso de camundongos SwissWebster). A contagem dos reticulócitos foi realizada em câmara de Neubauer. Apresentações de 4000 UI/mL foram avaliadas utilizando um material de referência de trabalho de alfaepoetina (3773 UI/mL) anteriormente testado frente ao padrão de referência internacional BRP (European Pharmacopeia Biological Reference Preparation). Os resultados indicam que camundongosdas colônias e linhagens examinadas respondem de forma satisfatória e podem serutilizados como alternativas ao hibrido B6D2F1 no ensaio de potência de alfaepoetina. Os camundongos BALB/c, entretanto, foram os que responderam deforma mais semelhante aos híbridos B6D2F1 no ensaio de potência da EPOhr em termos dos coeficientes angulares e lineares da curva dose-resposta (curvas paralelas praticamente superpostas).Instituto Nacional de Controle de Qualidade em Saúde2013-08-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion"Peer-reviewed article""Artículo revisado por pares""Artigo avaliado pelos pares"application/pdfhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/8910.3395/vd.v1n3.89Health Surveillance under Debate: Society, Science & Technology ; Vol. 1 No. 3 (2013): August; 49 - 58Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 1 Núm. 3 (2013): Agosto; 49 - 58Vigil Sanit Debate, Rio de Janeiro; v. 1 n. 3 (2013): Agosto; 49 - 582317-269Xreponame:Vigilância Sanitária em Debateinstname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZporhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89/60Copyright (c) 2013 Vigilância Sanitária em Debate: Sociedade, Ciência & Tecnologia (Health Surveillance under Debate: Society, Science & Technology) – Visa em Debatehttps://creativecommons.org/licenses/by-nc-nd/4.0info:eu-repo/semantics/openAccessSilva, Igor BarbosaMattos, Katherine AntunesDick, Paulo CesarAlmeida, Alessandra SantosSilva, Ricardo GonçalvesHokama, Darcy AkemiPaumgartten, Francisco José Roma2023-06-27T14:55:27Zoai:ojs.visaemdebate.incqs.fiocruz.br:article/89Revistahttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebatePUBhttps://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/oaiincqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br2317-269X2317-269Xopendoar:2023-06-27T14:55:27Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ)false |
dc.title.none.fl_str_mv |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 Ensaio de potência da alfaepoetina: Comparação de camundongos Swiss Webster, NIH, C57BL6, BALB/c com o híbrido B6D2F1 |
title |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 |
spellingShingle |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 Silva, Igor Barbosa epoetin alpha Potency assay bioassay mouse strains human erythropoietin recombinant (rhEPO) Alfaepoetina ensaio de potência bioensaio linhagens de camundongos eritropoietina recombiante humana (EPOhr) |
title_short |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 |
title_full |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 |
title_fullStr |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 |
title_full_unstemmed |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 |
title_sort |
Potency assay of epoetin alpha: Comparison of Swiss Webster, NIH, C57BL6, BALB/c mice with the hybrid B6D2F1 |
author |
Silva, Igor Barbosa |
author_facet |
Silva, Igor Barbosa Mattos, Katherine Antunes Dick, Paulo Cesar Almeida, Alessandra Santos Silva, Ricardo Gonçalves Hokama, Darcy Akemi Paumgartten, Francisco José Roma |
author_role |
author |
author2 |
Mattos, Katherine Antunes Dick, Paulo Cesar Almeida, Alessandra Santos Silva, Ricardo Gonçalves Hokama, Darcy Akemi Paumgartten, Francisco José Roma |
author2_role |
author author author author author author |
dc.contributor.author.fl_str_mv |
Silva, Igor Barbosa Mattos, Katherine Antunes Dick, Paulo Cesar Almeida, Alessandra Santos Silva, Ricardo Gonçalves Hokama, Darcy Akemi Paumgartten, Francisco José Roma |
dc.subject.por.fl_str_mv |
epoetin alpha Potency assay bioassay mouse strains human erythropoietin recombinant (rhEPO) Alfaepoetina ensaio de potência bioensaio linhagens de camundongos eritropoietina recombiante humana (EPOhr) |
topic |
epoetin alpha Potency assay bioassay mouse strains human erythropoietin recombinant (rhEPO) Alfaepoetina ensaio de potência bioensaio linhagens de camundongos eritropoietina recombiante humana (EPOhr) |
description |
In this study we compared the outcomes of epoetin alpha (rhEPO) potency assays performed with Swiss Webster, NIH, C57BL/6 and BALB/c mice with those of the assay conducted with the B6D2F1 hybrid, the only mice recommended by the European Pharmacopoeia (EP). Female mice from different breeding stocks and strains, weighing 16-18 g, received a single subcutaneous injection of (30, 90 or 270 IU per mouse, 0.2 mL per mouse) of rhEPO. Biological potencies of 4000 IU/mL rhEPO pharmaceutical forms from different batches were determined using a biological reference preparation (3773 IU/mL) previously tested against the international reference standard BRP (European Pharmacopoeia Biological Reference Preparation). Results showed that assays with mice from all tested breeding stocks and strains met EP statistical criteria for a valid erythropoietin potency assay and thus they are potential alternatives to the use of B6D2F1 hybrids. The assays with BALB/c mice, however, were those the results of which were most similar to those obtained with the hybrid regarding average reticulocyte counts in response to 30, 90 and 270 IU/mouse, angular (slope) and linear (intersection) coefficients of the linear dose-response curve (parallel and almost complete overlapping dose-response curves). |
publishDate |
2013 |
dc.date.none.fl_str_mv |
2013-08-30 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion "Peer-reviewed article" "Artículo revisado por pares" "Artigo avaliado pelos pares" |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89 10.3395/vd.v1n3.89 |
url |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89 |
identifier_str_mv |
10.3395/vd.v1n3.89 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://visaemdebate.incqs.fiocruz.br/index.php/visaemdebate/article/view/89/60 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-nd/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
publisher.none.fl_str_mv |
Instituto Nacional de Controle de Qualidade em Saúde |
dc.source.none.fl_str_mv |
Health Surveillance under Debate: Society, Science & Technology ; Vol. 1 No. 3 (2013): August; 49 - 58 Vigilancia en Salud en Debate: Sociedad, Ciencia y Tecnología; Vol. 1 Núm. 3 (2013): Agosto; 49 - 58 Vigil Sanit Debate, Rio de Janeiro; v. 1 n. 3 (2013): Agosto; 49 - 58 2317-269X reponame:Vigilância Sanitária em Debate instname:Fundação Oswaldo Cruz (FIOCRUZ) instacron:FIOCRUZ |
instname_str |
Fundação Oswaldo Cruz (FIOCRUZ) |
instacron_str |
FIOCRUZ |
institution |
FIOCRUZ |
reponame_str |
Vigilância Sanitária em Debate |
collection |
Vigilância Sanitária em Debate |
repository.name.fl_str_mv |
Vigilância Sanitária em Debate - Fundação Oswaldo Cruz (FIOCRUZ) |
repository.mail.fl_str_mv |
incqs.visaemdebate@fiocruz.br || gisele.neves@fiocruz.br |
_version_ |
1797042043370864640 |